Randomized phase II trial of temsirolimus (NCIi-supplied agent, NSC # 683864, IND # 61010) or the combination of hormonal therapy plus temsirolimus in women with advanced, persistent, or recurrent endometrial carcinoma

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT00729586?term=GOG-0248&rank=1

2. Intervention

   Megestrol acetate

3. Intervention

   Tamoxifen citrate

4. Intervention

   Temsirolimus

5. Additional Topic(s)

   Antineoplastic combined chemotherapy protocols

6. Resource Description

   Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of endometrial cancer cells. Hormone therapy using megestrol and tamoxifen may fight endometrial cancer by blocking the use of estrogen by the tumor cells. It is not yet known whether temsirolimus is more effective when given alone or together with megestrol and tamoxifen in treating endometrial cancer. This randomized phase II trial is studying temsirolimus to see how well it works with or without megestrol and tamoxifen in treating patients with advanced, persistent, or recurrent endometrial cancer.

7. Contact

   Berenberg, Jeffrey

8. PI

   Berenberg, Jeffrey

9. Topic

   endometrial cancer

10. Study Population

    Females with histologically confirmed endometrial carcinoma.

11. Website(s)

    http://www.cancer.gov/clinicaltrials/search/view?cdrid=609740&version=healthprofessional

12. Funded by

    Gynecologic Oncology Group

13. Phase

    Phase 2 clinical trial

14. Performed by

    Clinical Protocol & Data Management Shared Resource